Stipple Bio

Stipple Bio is a preclinical precision-oncology biotechnology company based in Cambridge, Massachusetts, founded in 2022 by cancer-biology researchers Aaron Ring (Fred Hutch) and Aashish Manglik (UCSF). Its Pointillist Platform performs cellular profiling and tumor-specific epitope discovery to design antibody binders and antibody-drug conjugates (ADCs) that target tumor-specific cell-surface epitopes while avoiding on-target, off-tumor toxicity. Its lead asset, STP-100, is an ADC advancing toward early clinical studies. The company emerged from stealth in April 2026 with an oversubscribed $100M Series A co-led by RA Capital, a16z Bio+Health and Nextech Invest, with participation from Google Ventures (gv). As a therapeutics company, Stipple Bio publishes no public API, developer portal, or software developer surface.

Stipple Bio is profiled on the APIs.io network. Tagged areas include Company, Life Sciences, Biotechnology, Oncology, and Precision Medicine.

🌐 Visit website 📡 Source on GitHub
3.3/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0
0 APIs
CompanyLife SciencesBiotechnologyOncologyPrecision MedicineDrug DiscoveryTherapeuticsAntibody-Drug Conjugates

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0
Composite quality — 3.3/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.0 / 17
Access Clarity 0.0 / 17
Operational Transparency 0.0 / 11
Contract Governance 0.0 / 10
Discoverability 4.3 / 9
Regulatory Posture 1.1 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
Documented Reversibility 0 / 6
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/stipple-bio: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Stipple Bio Domain Security

TLSv1.3

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Company 1

The organization behind the API

Website
Website

Source (apis.yml)

apis.yml Raw ↑ 
aid: stipple-bio
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/stipple-bio.png
name: Stipple Bio
description: Stipple Bio is a preclinical precision-oncology biotechnology company based in Cambridge, Massachusetts, founded
  in 2022 by cancer-biology researchers Aaron Ring (Fred Hutch) and Aashish Manglik (UCSF). Its Pointillist Platform performs
  cellular profiling and tumor-specific epitope discovery to design antibody binders and antibody-drug conjugates (ADCs) that
  target tumor-specific cell-surface epitopes while avoiding on-target, off-tumor toxicity. Its lead asset, STP-100, is an
  ADC advancing toward early clinical studies. The company emerged from stealth in April 2026 with an oversubscribed $100M
  Series A co-led by RA Capital, a16z Bio+Health and Nextech Invest, with participation from Google Ventures (gv). As a therapeutics
  company, Stipple Bio publishes no public API, developer portal, or software developer surface.
url: https://raw.githubusercontent.com/api-evangelist/stipple-bio/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- gv
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-21'
tags:
- Company
- Life Sciences
- Biotechnology
- Oncology
- Precision Medicine
- Drug Discovery
- Therapeutics
- Antibody-Drug Conjugates
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/stipple-bio-domain-security.yml
- type: Website
  url: https://stipple.bio
x-enrichment:
  date: '2026-07-21'
  status: minimal
  artifacts_added: 1
  pass: local-v1